Cargando…

Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant

There is a strong biologic rationale that poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors may benefit a broader range of metastatic breast cancer (MBC) patients than covered by current approvals, which require a germline BRCA1/2 sequence variant affecting function. We report a patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuemmel, Sherko, Harrach, Hakima, Schmutzler, Rita K., Kostara, Athina, Ziegler-Löhr, Katja, Dyson, Mark H., Chiari, Ouafaa, Reinisch, Mattea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382468/ https://www.ncbi.nlm.nih.gov/pubmed/32728620 http://dx.doi.org/10.1038/s41523-020-00174-9

Ejemplares similares

Next-Generation Sequencing-Directed Therapy in Patients with Metastatic Breast Cancer in Routine Clinical Practice
por: Bruzas, Simona, et al.
Publicado: (2021)

Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany
por: Reinisch, Mattea, et al.
Publicado: (2023)

Two progressed malignant phyllodes tumors of the breast harbor alterations in genes frequently involved in other advanced cancers
por: Reinisch, Mattea, et al.
Publicado: (2021)

Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy
por: Reinisch, Mattea, et al.
Publicado: (2023)

Gene signatures in patients with early breast cancer and relapse despite pathologic complete response
por: Bruzas, Simona, et al.
Publicado: (2022)

Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance
por: Horak, Peter, et al.
Publicado: (2019)

Evolutionary Origin of Human PALB2 Germline Pathogenic Variants
por: Chian, Jia Sheng, et al.
Publicado: (2023)

Germline PALB2 Mutations in Cancers and Its Distinction From Somatic PALB2 Mutations in Breast Cancers
por: Hu, Zhe-Yu, et al.
Publicado: (2020)

Tumour morphology predicts PALB2 germline mutation status
por: Teo, Z L, et al.
Publicado: (2013)

Report of a germline double heterozygote in MSH2 and PALB2
por: Agiannitopoulos, Konstantinos, et al.
Publicado: (2020)

A germline PALB2 pathogenic variant identified in a pediatric high-grade glioma
por: Zhong, Yiming, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer
por: Li, Na, et al.
Publicado: (2021)

A novel germline PALB2 deletion in Polish breast and ovarian cancer patients
por: Dansonka-Mieszkowska, Agnieszka, et al.
Publicado: (2010)

Germline PALB2 Mutation in High-Risk Chinese Breast and/or Ovarian Cancer Patients
por: Kwong, Ava, et al.
Publicado: (2021)

Familial wild-type gastrointestinal stromal tumour in association with germline truncating variants in both SDHA and PALB2
por: Whitworth, James, et al.
Publicado: (2021)

Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
por: Ma, Yi, et al.
Publicado: (2018)

Splicing predictions, minigene analyses, and ACMG‐AMP clinical classification of 42 germline PALB2 splice‐site variants
por: Valenzuela‐Palomo, Alberto, et al.
Publicado: (2021)

Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib
por: Hammel, P, et al.
Publicado: (2019)

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
por: Yang, Hong, et al.
Publicado: (2020)

PALB2 germline mutations in a large cohort of Middle Eastern breast-ovarian cancer patients
por: Siraj, Abdul K., et al.
Publicado: (2023)

Spectrum of PALB2 germline mutations and characteristics of PALB2‐related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next‐generation sequencing
por: Zhou, Jiaojiao, et al.
Publicado: (2020)

Efficacy and Safety of Auricular Acupuncture for the Treatment of Insomnia in Breast Cancer Survivors: A Randomized Controlled Trial
por: Höxtermann, Melanie D., et al.
Publicado: (2021)

Prevalence of PALB2 Germline Mutations in Early-onset and Familial Breast/Ovarian Cancer Patients from Pakistan
por: Rashid, Muhammad Usman, et al.
Publicado: (2019)

A rare PALB2 germline variant causing G2/M cell cycle arrest is associated with isolated myelosarcoma in infancy
por: Beer, Angelina, et al.
Publicado: (2021)

Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment
por: Mukherjee, Shibani, et al.
Publicado: (2020)

Information needs on breast cancer genetic and non-genetic risk factors in relatives of women with a BRCA1/2 or PALB2 pathogenic variant
por: Brédart, Anne, et al.
Publicado: (2021)

A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation
por: Wang, Huan, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial
por: Zhan, Mei, et al.
Publicado: (2020)

Prolonged response on olaparib maintenance in metastatic pancreatic acinar cell carcinoma associated with a germline BRCA 2 mutation, revealed by severe panniculitis
por: Lelong, Margaux, et al.
Publicado: (2022)

Functional characterization of 84 PALB2 variants of uncertain significance
por: Wiltshire, Timothy, et al.
Publicado: (2019)

The Contribution of Germline Pathogenic Variants in Breast Cancer Genes to Contralateral Breast Cancer Risk in BRCA1/BRCA2/PALB2-Negative Women
por: Larionov, Alexey, et al.
Publicado: (2023)

Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis
por: Exman, Pedro, et al.
Publicado: (2019)

Case Report: Co-Existence of BRCA2 and PALB2 Germline Mutations in Familial Prostate Cancer With Solitary Lung Metastasis
por: Tang, Tang, et al.
Publicado: (2020)

Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
por: Wattenberg, Max M., et al.
Publicado: (2019)

Case report: olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant
por: Soon Jian Hao, Jonathan, et al.
Publicado: (2022)

Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline BRCA1 Mutation after Progression on FOLFIRINOX: Case Report and Literature Review
por: Pimenta, Jefferson Rios, et al.
Publicado: (2020)

Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2021)

Germline PALB2, ATM variants in a patient with breast and ovarian cancer at risk for familial cancer syndrome: Is there a role for risk-reducing salpingo-oophorectomy?
por: Carbajal-Mamani, Semiramis L., et al.
Publicado: (2020)

Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report
por: Inoue, Kayo, et al.
Publicado: (2020)

Case Report: Effectiveness of Targeted Treatment in a Patient With Pancreatic Cancer Harboring PALB2 Germline Mutation and KRAS Somatic Mutation
por: Wu, Wei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_014baqvpsev1vt1fi6u6vbconf